Suerie Moon
Biographic Data
| ID | 6066219 |
|---|---|
| NAME | Suerie Moon |
| GIVEN NAMES | Suerie |
| FAMILY NAME | Moon |
| SIGNATURE | MOON S |
| AFFILIATIONS | Global Health Centre |
| ORCID | 0000-0001-8504-1212 |
| VERIFIED | Yes |
| TOTAL WORKS | 14 |
| TOTAL CITATIONS | 12 |
| WORKS AS AUTHOR | 14 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2008 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 1 |
Orchestrating faster access to products of non-profit R&D
INTRODUCTION: Non-profit product development partnerships (PDPs) have succeeded in bringing nearly 80 new drugs, vaccines and diagnostics for neglected diseases through regulatory approval, but arrangements to ensure they reach patients are unclear since the usual commercial incentives do not apply. We conducted a case study of how unusually fast access was achieved to a new treatment regimen for drug-resistant tuberculosis (DR-TB) developed by t…
Beyond resistance
Accelerating the development, equitable access to, and stewardship of new antibiotics is critical to protect public health and address antimicrobial resistance (AMR). To understand and assess how the current antibiotics innovation sub-system – or ‘niche’ – addresses this task, we reviewed the literature, compiled and analyzed a database of 211 antibiotic developers, and conducted 10 stakeholder interviews. We found that the mainstream market-driv…
The 30-year evolution of oral cholera vaccines
Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas. The development of OCVs was made possible through an alternative innovation model, which sustaine…
Developing globally-accessible medicines for pandemic preparedness
Recent infectious disease crises (e.g. COVID-19, Ebola, mpox) show that the mainstream market-driven innovation model cannot ensure both rapid innovation and equitable global access to vaccines, drugs, and diagnostics critical for pandemic preparedness and response. Alternative models that may better address global access needs exist, but analysis of their merits is limited. We analysed the pharmaceutical innovation 'niche' for pandemic products …
Which roads lead to access? A global landscape of six Covid-19 vaccine innovation models
BACKGROUND: Unequal and inequitable access to Covid-19 vaccines in low- and middle-income countries (L&MICs) was a major political, ethical and public health failure in the pandemic. However, vaccine developers' practices were not monolithic, but rather, took diverse approaches to supplying different countries, with important implications for global access. RESULTS: Using data on R&D investments, regulatory approvals, manufacturing and purchase a…
Global Governance in a World of Change
Global governance has come under increasing pressure since the end of the Cold War. In some issue areas, these pressures have led to significant changes in the architecture of governance institutions. In others, institutions have resisted pressures for change. This volume explores what accounts for this divergence in architecture by identifying three modes of governance: hierarchies, networks, and markets. The authors apply these ideal types to d…
Reimagining Global Health Governance in the Age of Covid-19
Power in global governance
The exercise of power permeates global governance processes, making power a critical concept for understanding, explaining, and influencing the intersection of global governance and health. This article briefly presents and discusses three well-established conceptualizations of power—Dahl’s, Bourdieu’s, and Barnett and Duvall’s—from different disciplines, finding that each is important for understanding global governance but none is sufficient. T…
Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola
The west African Ebola epidemic that began in 2013 exposed deep inadequacies in the national and international institutions responsible for protecting the public from the far-reaching human, social, economic, and political consequences of infectious disease outbreaks. The Ebola epidemic raised a crucial question: what reforms are needed to mend the fragile global system for outbreak prevention and response, rebuild confidence, and prevent future …
The political origins of health inequity
Despite large gains in health over the past few decades, the distribution of health risks worldwide remains extremely and unacceptably uneven. Although the health sector has a crucial role in addressing health inequalities, its eff orts often come into confl ict with powerful global actors in pursuit of other interests such as protection of national security, safeguarding of sovereignty, or economic goals. This is the starting point of The Lancet…
Governance Challenges in Global Health
Global health is at the threshold of a new era. Few times in his- tory has the world faced challenges as complex as those now posed by a trio of threats: first, the unfinished agenda of infections, undernutrition, and reproductive health problems; second, the rising global burden of noncommu- nicable diseases and their associated risk factors, such as smoking and obesity; and third, the challenges arising from globalization itself, such as the he…
A win-win solution
BACKGROUND: Tiered pricing - the concept of selling drugs and vaccines in developing countries at prices systematically lower than in industrialized countries - has received widespread support from industry, policymakers, civil society, and academics as a way to improve access to medicines for the poor. We carried out case studies based on a review of international drug price developments for antiretrovirals, artemisinin combination therapies, dr…
Intervening in global markets to improve access to HIV/Aids treatment
BACKGROUND: Universal access to antiretroviral therapy (ART) in low- and middle-income countries faces numerous challenges: increasing numbers of people needing ART, new guidelines recommending more expensive antiretroviral (ARV) medicines, limited financing, and few fixed-dose combination (FDC) products. Global initiatives aim to promote efficient global ARV markets, yet little is known about market dynamics and the impact of global policy inter…
Out-of-pocket costs of Aids care in China
Financial access to HIV care and treatment can be difficult for many people in China, where the government provides free antiretroviral drugs but does not cover the cost of other medically necessary components, such as lab tests and drugs for opportunistic infections. This article estimates out-of-pocket costs for treatment and care that a person living with HIV/AIDS in China might face over the course of one year. Data comes from two treatment p…
Out-of-pocket costs of Aids care in China
Financial access to HIV care and treatment can be difficult for many people in China, where the government provides free antiretroviral drugs but does not cover the cost of other medically necessary components, such as lab tests and drugs for opportunistic infections. This article estimates out-of-pocket costs for treatment and care that a person living with HIV/AIDS in China might face over the course of one year. Data comes from two treatment p…
Intervening in global markets to improve access to HIV/Aids treatment
BACKGROUND: Universal access to antiretroviral therapy (ART) in low- and middle-income countries faces numerous challenges: increasing numbers of people needing ART, new guidelines recommending more expensive antiretroviral (ARV) medicines, limited financing, and few fixed-dose combination (FDC) products. Global initiatives aim to promote efficient global ARV markets, yet little is known about market dynamics and the impact of global policy inter…
A win-win solution
BACKGROUND: Tiered pricing - the concept of selling drugs and vaccines in developing countries at prices systematically lower than in industrialized countries - has received widespread support from industry, policymakers, civil society, and academics as a way to improve access to medicines for the poor. We carried out case studies based on a review of international drug price developments for antiretrovirals, artemisinin combination therapies, dr…
Governance Challenges in Global Health
Global health is at the threshold of a new era. Few times in his- tory has the world faced challenges as complex as those now posed by a trio of threats: first, the unfinished agenda of infections, undernutrition, and reproductive health problems; second, the rising global burden of noncommu- nicable diseases and their associated risk factors, such as smoking and obesity; and third, the challenges arising from globalization itself, such as the he…
The political origins of health inequity
Despite large gains in health over the past few decades, the distribution of health risks worldwide remains extremely and unacceptably uneven. Although the health sector has a crucial role in addressing health inequalities, its eff orts often come into confl ict with powerful global actors in pursuit of other interests such as protection of national security, safeguarding of sovereignty, or economic goals. This is the starting point of The Lancet…
Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola
The west African Ebola epidemic that began in 2013 exposed deep inadequacies in the national and international institutions responsible for protecting the public from the far-reaching human, social, economic, and political consequences of infectious disease outbreaks. The Ebola epidemic raised a crucial question: what reforms are needed to mend the fragile global system for outbreak prevention and response, rebuild confidence, and prevent future …
Power in global governance
The exercise of power permeates global governance processes, making power a critical concept for understanding, explaining, and influencing the intersection of global governance and health. This article briefly presents and discusses three well-established conceptualizations of power—Dahl’s, Bourdieu’s, and Barnett and Duvall’s—from different disciplines, finding that each is important for understanding global governance but none is sufficient. T…
Reimagining Global Health Governance in the Age of Covid-19
Global Governance in a World of Change
Global governance has come under increasing pressure since the end of the Cold War. In some issue areas, these pressures have led to significant changes in the architecture of governance institutions. In others, institutions have resisted pressures for change. This volume explores what accounts for this divergence in architecture by identifying three modes of governance: hierarchies, networks, and markets. The authors apply these ideal types to d…
Which roads lead to access? A global landscape of six Covid-19 vaccine innovation models
BACKGROUND: Unequal and inequitable access to Covid-19 vaccines in low- and middle-income countries (L&MICs) was a major political, ethical and public health failure in the pandemic. However, vaccine developers' practices were not monolithic, but rather, took diverse approaches to supplying different countries, with important implications for global access. RESULTS: Using data on R&D investments, regulatory approvals, manufacturing and purchase a…
Beyond resistance
Accelerating the development, equitable access to, and stewardship of new antibiotics is critical to protect public health and address antimicrobial resistance (AMR). To understand and assess how the current antibiotics innovation sub-system – or ‘niche’ – addresses this task, we reviewed the literature, compiled and analyzed a database of 211 antibiotic developers, and conducted 10 stakeholder interviews. We found that the mainstream market-driv…
The 30-year evolution of oral cholera vaccines
Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas. The development of OCVs was made possible through an alternative innovation model, which sustaine…
Developing globally-accessible medicines for pandemic preparedness
Recent infectious disease crises (e.g. COVID-19, Ebola, mpox) show that the mainstream market-driven innovation model cannot ensure both rapid innovation and equitable global access to vaccines, drugs, and diagnostics critical for pandemic preparedness and response. Alternative models that may better address global access needs exist, but analysis of their merits is limited. We analysed the pharmaceutical innovation 'niche' for pandemic products …
Orchestrating faster access to products of non-profit R&D
INTRODUCTION: Non-profit product development partnerships (PDPs) have succeeded in bringing nearly 80 new drugs, vaccines and diagnostics for neglected diseases through regulatory approval, but arrangements to ensure they reach patients are unclear since the usual commercial incentives do not apply. We conducted a case study of how unusually fast access was achieved to a new treatment regimen for drug-resistant tuberculosis (DR-TB) developed by t…
Economics (8 works) · Medicine (7 works) · Business (6 works) · Pharmaceutical Economics and Policy (6 works) · Political science (6 works) · Economic growth (5 works) · Global health (5 works) · Health care (5 works) · Corporate governance (3 works) · Development economics (3 works)